- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03804073
Short Course Radiation Therapy in Palliative Treatment of Head and Neck Cancer
January 21, 2019 updated by: Alessio Giuseppe Morganti, IRCCS Azienda Ospedaliero-Universitaria di Bologna
SHort Course Accelerated RadiatiON Therapy (SHARON) in Palliative Treatment of Head and Neck Cancer: an Interventional, Randomized, Multicentric Study
Aim of the study is to assess efficacy of a short course radiation treatment in patients with symptomatic head and neck (H&N) malignant lesions
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Standard treatment for H&N lesions (3000 cGy in 10 daily fractions of 300 cGy each) is compared with experimental treatment (2000 cGy in 4 fractions of 500 cGy twice a day) to demonstrate non-inferiority of this scheme
Study Type
Interventional
Enrollment (Anticipated)
82
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
BO
-
Bologna, BO, Italy, 40138
- Recruiting
- Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine- DIMES, University of Bologna, S.Orsola-Malpighi Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- symptomatic H&N malignant lesions (primary solid tumors or metastases from solid tumor)
- age>18 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-3
- no changes in supportive care in the week before radiotherapy
Exclusion Criteria:
- pregnancy
- previous irradiation of the same region
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: standard treatment
patients in this group are treated with 3000 cGy in 10 daily fraction
|
3000 cGy in 10 daily fractions
|
Experimental: short course treatment
patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
|
2000 cGy in 4 fractions administered twice a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of palliation using the short course scheme compared with the standard scheme
Time Frame: 3 months
|
reduction of initial symptoms (pain, bleeding, dysphagia, hoarseness, stridor, dehydration, malnutrition) after radiotherapy, evaluated as none-mild-moderate-severe before and after treatment
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
acute toxicity in the two treatment groups
Time Frame: 3 months
|
incidence of treatment-related acute adverse events in the two arms of the study registered using Radiation Therapy Oncology Group (RTOG) Cooperative Group Common Toxicity Criteria
|
3 months
|
late toxicity in the two treatment groups
Time Frame: 12 months
|
incidence of treatment-related adverse events in the two arms of the study registered using RTOG/European Organisation for Research and Treatment of Cancer(EORTC) Late Radiation Morbility Scoring Schema
|
12 months
|
Quality of Life (QoL) assessment in the two groups
Time Frame: 12 months
|
changes in QoL after treatment assessed using a specific EORTC questionnaire developed to assess the quality of life of palliative cancer care patients (C15-PAL)
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Alessio G Morganti, MD, Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine-DIMES, Unversity of Bologna, S. Orsola-Malpighi Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 8, 2017
Primary Completion (Anticipated)
November 8, 2022
Study Completion (Anticipated)
November 8, 2023
Study Registration Dates
First Submitted
January 11, 2019
First Submitted That Met QC Criteria
January 14, 2019
First Posted (Actual)
January 15, 2019
Study Record Updates
Last Update Posted (Actual)
January 23, 2019
Last Update Submitted That Met QC Criteria
January 21, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RT 15-05 SHARON HEAD AND NECK
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
Centre Oscar LambretUnknownEpidermoid Head and Neck CancerFrance
Clinical Trials on standard treatment
-
Paul CrawfordCompleted
-
Hospital Clinic of BarcelonaUnknown
-
Hospices Civils de LyonTerminatedAnal IncontinenceFrance
-
BaroPace Inc.JSS Medical Research Inc.RecruitingHypertension | Heart Failure With Preserved Ejection Fraction (HFpEF)India
-
The University of Hong KongNot yet recruitingStroke | Small Vessel Cerebrovascular Disease
-
Yale UniversityNational Institutes of Health (NIH)Completed
-
Pharmazz, Inc.CompletedHypovolemic ShockIndia
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingThoracic Cancer | Palliative Care | RadiotherapyItaly
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingPelvic Cancer | Palliative Care | RadiotherapyItaly
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingPalliative Care | Brain Metastases | RadiotherapyItaly